S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bruker Co. stock logo
BRKR
Bruker
$77.76
-1.0%
$87.78
$53.79
$94.86
$10.71B1.17797,744 shs1.31 million shs
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$5.92
-0.7%
$7.23
$3.80
$12.31
$774.45M1.37744,028 shs421,927 shs
HORIBA, Ltd. stock logo
HRIBF
HORIBA
$98.40
$93.13
$51.03
$100.67
N/A0.313,400 shsN/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
$27.94
-3.5%
$39.76
$26.75
$63.57
$3.33B1.91.46 million shs2.08 million shs
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bruker Co. stock logo
BRKR
Bruker
-5.28%-12.98%-14.61%+9.20%-5.18%
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
+0.68%-5.40%-11.04%-27.93%-38.81%
HORIBA, Ltd. stock logo
HRIBF
HORIBA
0.00%+4.70%+4.70%+45.69%+73.97%
10x Genomics, Inc. stock logo
TXG
10x Genomics
-0.72%-20.36%-22.66%-30.74%-47.36%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bruker Co. stock logo
BRKR
Bruker
4.7858 of 5 stars
2.24.01.73.82.14.23.1
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
2.0138 of 5 stars
3.30.00.00.03.73.30.6
HORIBA, Ltd. stock logo
HRIBF
HORIBA
N/AN/AN/AN/AN/AN/AN/AN/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
4.184 of 5 stars
3.42.00.04.82.43.30.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bruker Co. stock logo
BRKR
Bruker
2.43
Hold$84.869.13% Upside
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
2.60
Moderate Buy$9.0052.03% Upside
HORIBA, Ltd. stock logo
HRIBF
HORIBA
N/AN/AN/AN/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
2.89
Moderate Buy$60.22115.54% Upside

Current Analyst Ratings

Latest TXG, BRKR, HRIBF, and CTKB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/18/2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$60.00 ➝ $55.00
4/10/2024
Bruker Co. stock logo
BRKR
Bruker
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSell ➝ Sell$66.00 ➝ $74.00
4/10/2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$55.00 ➝ $45.00
3/6/2024
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$11.00 ➝ $10.00
3/1/2024
Bruker Co. stock logo
BRKR
Bruker
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$94.00 ➝ $102.00
2/29/2024
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$9.00 ➝ $10.00
2/16/2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$68.00 ➝ $63.00
2/15/2024
Bruker Co. stock logo
BRKR
Bruker
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$86.00 ➝ $94.00
2/14/2024
Bruker Co. stock logo
BRKR
Bruker
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$80.00 ➝ $95.00
2/14/2024
Bruker Co. stock logo
BRKR
Bruker
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$63.00 ➝ $81.00
2/14/2024
Bruker Co. stock logo
BRKR
Bruker
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$60.00 ➝ $90.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bruker Co. stock logo
BRKR
Bruker
$2.96B3.61$3.35 per share23.21$10.08 per share7.71
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$193.01M4.01$0.03 per share234.70$2.90 per share2.04
HORIBA, Ltd. stock logo
HRIBF
HORIBA
$1.97BN/A$8.19 per share12.02$43.98 per shareN/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
$618.73M5.38N/AN/A$6.22 per share4.49

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bruker Co. stock logo
BRKR
Bruker
$427.20M$2.9226.6322.602.1014.41%29.94%9.68%5/2/2024 (Estimated)
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-$12.15M-$0.09N/A84.57N/A-6.29%-1.40%-1.13%5/14/2024 (Estimated)
HORIBA, Ltd. stock logo
HRIBF
HORIBA
$272.92M$6.9014.2616.45N/A13.95%13.25%8.11%N/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$255.10M-$2.17N/AN/AN/A-41.17%-28.82%-22.67%4/30/2024 (Confirmed)

Latest TXG, BRKR, HRIBF, and CTKB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/30/2024N/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$0.46N/A+$0.46N/AN/AN/A  
2/15/2024Q4 2023
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$0.36-$0.41-$0.05-$0.41$182.73 million$183.98 million    
2/14/2024Q4 2023
HORIBA, Ltd. stock logo
HRIBF
HORIBA
N/A$2.41+$2.41$2.58N/A$641.02 million
2/13/202412/31/2023
Bruker Co. stock logo
BRKR
Bruker
$0.65$0.70+$0.05-$0.01$809.35 million$844.50 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bruker Co. stock logo
BRKR
Bruker
$0.200.26%+7.72%6.85%N/A
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
N/AN/AN/AN/AN/A
HORIBA, Ltd. stock logo
HRIBF
HORIBA
N/AN/AN/AN/AN/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
N/AN/AN/AN/AN/A

Latest TXG, BRKR, HRIBF, and CTKB Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/15/2024
Bruker Co. stock logo
BRKR
Bruker
Quarterly$0.050.25%2/29/20243/1/20243/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bruker Co. stock logo
BRKR
Bruker
0.83
1.80
0.99
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
N/A
6.97
5.89
HORIBA, Ltd. stock logo
HRIBF
HORIBA
0.20
3.05
2.03
10x Genomics, Inc. stock logo
TXG
10x Genomics
N/A
4.69
4.11

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Bruker Co. stock logo
BRKR
Bruker
79.52%
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
69.46%
HORIBA, Ltd. stock logo
HRIBF
HORIBA
N/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
84.68%

Insider Ownership

CompanyInsider Ownership
Bruker Co. stock logo
BRKR
Bruker
28.20%
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
15.90%
HORIBA, Ltd. stock logo
HRIBF
HORIBA
N/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
10.65%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Bruker Co. stock logo
BRKR
Bruker
9,707137.67 million98.85 millionOptionable
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
676130.82 million110.02 millionOptionable
HORIBA, Ltd. stock logo
HRIBF
HORIBA
8,432N/AN/ANot Optionable
10x Genomics, Inc. stock logo
TXG
10x Genomics
1,259119.17 million106.48 millionOptionable

TXG, BRKR, HRIBF, and CTKB Headlines

SourceHeadline
10x Genomics (NASDAQ:TXG) Shares Gap Down  on Analyst Downgrade10x Genomics (NASDAQ:TXG) Shares Gap Down on Analyst Downgrade
americanbankingnews.com - April 19 at 1:14 AM
Bruker to acquire Nanostring for $393MBruker to acquire Nanostring for $393M
medtechdive.com - April 18 at 3:02 PM
10x Genomics (NASDAQ:TXG) Shares Gap Down  Following Analyst Downgrade10x Genomics (NASDAQ:TXG) Shares Gap Down Following Analyst Downgrade
marketbeat.com - April 18 at 10:35 AM
10x Genomics (NASDAQ:TXG) PT Lowered to $55.0010x Genomics (NASDAQ:TXG) PT Lowered to $55.00
marketbeat.com - April 18 at 8:34 AM
10x Genomics, Inc. (TXG)10x Genomics, Inc. (TXG)
finance.yahoo.com - April 17 at 12:34 PM
10x Genomics (NASDAQ:TXG) Trading Down 5.9%10x Genomics (NASDAQ:TXG) Trading Down 5.9%
marketbeat.com - April 16 at 1:41 PM
10x Genomics, Inc. (NASDAQ:TXG) Shares Bought by Sumitomo Mitsui Trust Holdings Inc.10x Genomics, Inc. (NASDAQ:TXG) Shares Bought by Sumitomo Mitsui Trust Holdings Inc.
marketbeat.com - April 16 at 7:22 AM
SVB Wealth LLC Has $80.95 Million Position in 10x Genomics, Inc. (NASDAQ:TXG)SVB Wealth LLC Has $80.95 Million Position in 10x Genomics, Inc. (NASDAQ:TXG)
marketbeat.com - April 15 at 10:06 PM
10x Genomics (NASDAQ:TXG) Hits New 52-Week Low at $33.4710x Genomics (NASDAQ:TXG) Hits New 52-Week Low at $33.47
marketbeat.com - April 15 at 2:48 PM
10x Genomics (NASDAQ:TXG) Shares Gap Down  After Analyst Downgrade10x Genomics (NASDAQ:TXG) Shares Gap Down After Analyst Downgrade
americanbankingnews.com - April 12 at 5:26 AM
Cathie Woods ARK focuses on Teladoc and 10X Genomics stockCathie Wood's ARK focuses on Teladoc and 10X Genomics stock
investing.com - April 11 at 7:21 PM
10x Genomics (NASDAQ:TXG) Price Target Cut to $45.00 by Analysts at Barclays10x Genomics (NASDAQ:TXG) Price Target Cut to $45.00 by Analysts at Barclays
americanbankingnews.com - April 11 at 4:58 AM
10x Genomics to Report First Quarter 2024 Financial Results on April 30, 202410x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024
finance.yahoo.com - April 10 at 7:03 PM
10x Genomics (NASDAQ:TXG) Price Target Cut to $45.0010x Genomics (NASDAQ:TXG) Price Target Cut to $45.00
marketbeat.com - April 10 at 4:19 PM
10x Genomics to Report First Quarter 2024 Financial Results on April 30, 202410x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024
prnewswire.com - April 10 at 4:05 PM
10x Genomics (NASDAQ:TXG) Shares Gap Down to $37.3710x Genomics (NASDAQ:TXG) Shares Gap Down to $37.37
marketbeat.com - April 10 at 11:50 AM
Baillie Gifford & Co. Decreases Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG)Baillie Gifford & Co. Decreases Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG)
marketbeat.com - April 9 at 12:12 PM
As 10x Launches Visium HD, Will Single Cell Resolution Draw New Customers?As 10x Launches Visium HD, Will Single Cell Resolution Draw New Customers?
genengnews.com - March 29 at 5:58 PM
ARK Investment Management LLC Acquires 1,047,827 Shares of 10x Genomics, Inc. (NASDAQ:TXG)ARK Investment Management LLC Acquires 1,047,827 Shares of 10x Genomics, Inc. (NASDAQ:TXG)
marketbeat.com - March 28 at 6:39 AM
10x Genomics, Inc. (NASDAQ:TXG) Shares Acquired by Vanguard Group Inc.10x Genomics, Inc. (NASDAQ:TXG) Shares Acquired by Vanguard Group Inc.
marketbeat.com - March 27 at 4:25 AM
10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay
finance.yahoo.com - March 26 at 1:11 PM
10x Genomics, Inc: 10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel10x Genomics, Inc: 10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel
finanznachrichten.de - March 23 at 12:22 PM
10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel
finance.yahoo.com - March 21 at 4:46 PM
TXG Nov 2024 40.000 putTXG Nov 2024 40.000 put
ca.finance.yahoo.com - March 16 at 2:48 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Bruker logo

Bruker

NASDAQ:BRKR
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Cytek Biosciences logo

Cytek Biosciences

NASDAQ:CTKB
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
HORIBA logo

HORIBA

OTCMKTS:HRIBF
HORIBA, Ltd. manufactures and sells instruments and systems worldwide. The company operates in five segments: Automotive, Environment/Process, Medical, Semiconductor, and Scientific. The Automotive segment offers engine emission measurement devices; in-use vehicle emission measurement devices; on-board emission measurement devices; in-vehicle exhaust gas measuring devices; driveline test systems; engine test systems; brake test systems; fuel cell test devices; battery test devices; and vehicle development engineering and test engineering services, as well as leases and manages research and development facilities. The Environment/Process segment provides flue gas analyzers, water quality measuring devices, air pollution monitoring analyzers, environmental radiation measuring instruments, and process measurement equipment. The Medical segment offers hematology and CRP, immunology, clinical chemistry, and blood glucose analyzers, blood cell counters, biochemical testing devices, blood glucose testing devices, as well as coagulation/hemostasis analyzers. The Semiconductor segment provides mass flow controllers, chemical concentration monitors, semiconductor contaminant inspection equipment, and residual gas analyzer. The Scientific segment offers Raman spectrometers, pH meters, water quality measuring devices, particle size distribution measuring devices, X -ray fluorescence analyzers, elemental analyzers, fluorescence spectroscopy/lifetime measurement devices, spectrometer/detectors, and gratings. It also engages in the fund management, software development, and automation software for engine. The company's products are used in arts, entertainment, and recreation; education, research and development, and government institution; food and beverage; energy and environment; health care; industrials; information technology; water; materials; mobility and transport; and waste management applications. HORIBA, Ltd. was founded in 1945 and is headquartered in Kyoto, Japan.
10x Genomics logo

10x Genomics

NASDAQ:TXG
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.